

## Olon completes acquisition of Mahad plant

08 April 2019 | News

**Olon intends to invest in the site and pursue business development opportunities to optimize the plant's utilization and expand its customer base.**



OlonS.p.A., a world leading Active Pharmaceutical Ingredients (API) contract development and manufacturing organization (CDMO) and generics supplier, has announced the closing of the acquisition of the manufacturing facility in Mahad, India.

After an intensive transition period started on September 4<sup>th</sup>, Olon India will start definitively all the activities the next April 1st according to the strategy of Olon S.p.A.

Paolo Tubertini, CEO of Olon, commented, "With this acquisition Olon achieved another successful milestone toward our growing strategy. Following the acquisition of Ricerca Biosciences' Chemical Division in mid-2017 and Capua BioServices S.p.A. - the global provider of CDMO services in the field microbial fermentation in January 2019 - we have now completed a further step in our strategic plan. With this acquisition, Olon has successfully finalized its 3 years' development plan, we will move to the next target: to play an important role in the manufacturing of biologics API's."

After the carve out from Sandoz, as part of the asset purchase agreement, the parties have committed to sign a long-term supply contract to guarantee continuous supply of products manufactured in Mahad. The plant's main product is Rifampicin - used to treat several types of bacterial infections, including tuberculosis - and its derivate.

Olon intends to invest in the site and pursue business development opportunities to optimize the plant's utilization and expand its customer base.

The new company Olon API India Pvt Ltd. has already launched important investment project, establishing a new head office in Mumbai, hiring additional people, improving the organization and Indian market presence and beginning a Technology Transfer introducing new production to the Mahad site.

The Mahad site, which supplies products to Sandoz, a division of the Novartis Group, is an established and reputable API manufacturing facility in India with a reaction capacity of 580 m<sup>3</sup> and approximately 270 employees. This site provides a number of lifesaving medicines to the Indian healthcare system and patients around the world, with a 2018 turnover equally divided between Indian and foreign markets.